Lincoln Pharmaceuticals LimitedQ2 FY27 Results & Financial Update
Lincoln Pharmaceuticals Limited: Q2 FY27 consolidated results and company financials – revenue ₹191.35 Cr, PAT ₹20.43 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Lincoln Pharmaceuticals price & chart
Market price₹545.60
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Lincoln Pharmaceuticals Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Lincoln Pharmaceuticals Limited reported consolidated revenue from operations of INR 191.35 crore for the quarter ended September 30, 2026, marking an increase compared to the previous quarter's revenue of INR 177.28 crore.
Total income for Q2 FY27 stood at INR 200.88 crore, shifting slightly from INR 201.55 crore recorded in the preceding quarter.
Profit before tax (PBT) for the quarter was reported at INR 29.02 crore, reflecting a sequential movement from INR 47.55 crore in Q1 FY27.
Profit after tax (PAT) for the current quarter stood at INR 20.43 crore, compared to INR 36.23 crore in the previous quarter, corresponding to a PAT margin of 10.68%.
Basic earnings per share (EPS) for Q2 FY27 was recorded at INR 10.20, compared with INR 18.09 in the preceding quarter.
Other income for the quarter came in at INR 9.53 crore, down from INR 24.26 crore reported in the previous quarter.
Total expenses during the period included finance costs of INR 0.32 crore, depreciation and amortization of INR 3.88 crore, tax expenses of INR 8.59 crore, and provisions amounting to INR 5.23 crore.
01 · Business model
What does Lincoln Pharmaceuticals do?
Lincoln Pharmaceuticals Limited operates as a pharmaceutical company, manufacturing and marketing a diverse portfolio of health products, formulations, and medical specialties across domestic and international markets.
The company's operational model focuses on developing broad therapeutic segments, managing manufacturing facilities, and expanding its geographic reach through export channels alongside domestic distribution.
Revenue generation is driven by pharmaceutical formulation sales, supplemented by other operating income streams such as interest income and auxiliary receipts.
02 · Financial snapshot
Current quarter vs the available comparable
| Metric | Q2 FY27 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹191.35 Cr | ₹177.28 Cr |
| Total income | ₹200.88 Cr | ₹201.55 Cr |
| Profit before tax | ₹29.02 Cr | ₹47.55 Cr |
| Profit after tax | ₹20.43 Cr | ₹36.23 Cr |
| EPS | ₹10.20 | ₹18.09 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 10.7% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 15.2% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹9.53 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations reached INR 191.35 crore in Q2 FY27, up from INR 177.28 crore in Q1 FY27.
Total income for the quarter stood at INR 200.88 crore, supported by total revenue and other income components including interest income of INR 3.69 crore.
What drove margins
PAT margin for Q2 FY27 stood at 10.68%, down from 20.44% in the previous quarter, reflecting changes in profitability relative to total income.
The company incurred finance costs of INR 0.32 crore and depreciation of INR 3.88 crore during the quarter.
04 · Reported developments
What changed operationally
Operating revenue grew sequentially to INR 191.35 crore in Q2 FY27 from INR 177.28 crore in Q1 FY27.
05 · Pressure points & risks
What is not going smoothly
Profit after tax declined sequentially to INR 20.43 crore in Q2 FY27 compared to INR 36.23 crore in Q1 FY27.
06 · Items worth noticing
The line items that can distort a quick read
The company reported provisions of INR 5.23 crore for the quarter ended September 30, 2026.
07 · Previous-quarter changes
What changed since the previous quarter
Revenue from operations increased by approximately 7.93% from INR 177.28 crore in Q1 FY27 to INR 191.35 crore in Q2 FY27.
PAT decreased by approximately 43.63% from INR 36.23 crore in Q1 FY27 to INR 20.43 crore in Q2 FY27.
08 · Key Q&A
The quarter, answered directly
What does Lincoln Pharmaceuticals do?
Lincoln Pharmaceuticals Limited operates as a pharmaceutical company, manufacturing and marketing a diverse portfolio of health products, formulations, and medical specialties across domestic and international markets.
What is the clearest takeaway from Q2 FY27?
Lincoln Pharmaceuticals Limited reported consolidated revenue from operations of INR 191.35 crore for the quarter ended September 30, 2026, marking an increase compared to the previous quarter's revenue of INR 177.28 crore.
What drove revenue or demand?
Revenue from operations reached INR 191.35 crore in Q2 FY27, up from INR 177.28 crore in Q1 FY27.
What mattered most for margins or profitability?
PAT margin for Q2 FY27 stood at 10.68%, down from 20.44% in the previous quarter, reflecting changes in profitability relative to total income.
What are the main pressure points disclosed for the quarter?
Profit after tax declined sequentially to INR 20.43 crore in Q2 FY27 compared to INR 36.23 crore in Q1 FY27.
What should the next disclosure help confirm?
Monitor subsequent quarterly filings to track revenue growth trends and profitability margins.
09 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
10 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Upcoming Financial Disclosures: Monitor subsequent quarterly filings to track revenue growth trends and profitability margins.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.